Recent Price Movement and Market Context
On 9 December 2025, Brooks Laboratories’ share price touched Rs.93.9, the lowest level recorded in the past year. This price point represents a decline of 1.26% on the day and an 11.25% reduction over the last nine consecutive trading days. The stock’s performance has underperformed its Pharmaceuticals & Biotechnology sector by 0.41% on the same day.
In comparison, the Sensex index experienced a fall of 207.75 points, or 0.67%, closing at 84,535.12. Despite this decline, the Sensex remains approximately 1.92% below its 52-week high of 86,159.02 and continues to trade above its 50-day moving average, which itself is positioned above the 200-day moving average, indicating a generally bullish trend for the broader market.
Brooks Laboratories’ stock is currently trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. This technical positioning highlights the stock’s relative weakness compared to both its sector and the overall market.
Our latest monthly pick, this Large Cap from Aluminium & Aluminium Products, is outperforming the market! See the analysis that helped our Investment Committee select this winner.
- - Market-beating performance
- - Committee-backed winner
- - Aluminium & Aluminium Products standout
Long-Term Performance and Financial Metrics
Over the past year, Brooks Laboratories has recorded a total return of -33.59%, a stark contrast to the Sensex’s positive return of 3.75% during the same period. The stock’s 52-week high was Rs.202.8, indicating a substantial reduction in value over the last twelve months.
Financially, the company’s long-term fundamentals show modest growth and limited profitability. Net sales have expanded at an annual rate of approximately 4.36% over the last five years, while the average return on equity (ROE) stands at 2.42%, reflecting subdued efficiency in generating shareholder returns.
Brooks Laboratories’ ability to service its debt is also constrained, with an average EBIT to interest ratio of -3.69, signalling challenges in covering interest expenses from operating earnings. Despite this, the company’s latest quarterly results indicate some positive trends, including a 170.3% rise in profits over the past year and a net sales growth of 26.45% in the most recent six-month period.
Valuation and Comparative Analysis
The stock’s valuation metrics reveal a price-to-book value ratio of 2.4, which is considered relatively expensive given the company’s ROE of 12.1%. However, Brooks Laboratories is trading at a discount compared to the average historical valuations of its peers within the Pharmaceuticals & Biotechnology sector.
Despite the recent decline, the company has reported positive results for four consecutive quarters, with operating cash flow for the year reaching Rs.2.63 crores and profit before tax excluding other income at Rs.7.59 crores, reflecting a growth rate of 2563.2% compared to the previous four-quarter average.
Shareholding and Sector Position
The majority shareholding in Brooks Laboratories remains with promoters, maintaining a stable ownership structure. The company operates within the Pharmaceuticals & Biotechnology sector, which has generally shown resilience and growth potential, although Brooks Laboratories’ stock has consistently underperformed the BSE500 index over the last three annual periods.
Is Brooks Laboratories your best bet? SwitchER suggests better alternatives across peers, market caps, and sectors. Discover stocks that could deliver more for your portfolio!
- - Better alternatives suggested
- - Cross-sector comparison
- - Portfolio optimization tool
Summary of Key Financial Indicators
Brooks Laboratories’ recent financial data presents a mixed picture. While net sales growth and profit increases in recent quarters are encouraging, the stock’s valuation and long-term returns remain subdued relative to sector benchmarks. The stock’s current trading below all major moving averages further emphasises the prevailing downward momentum.
In the context of the broader market, where the Sensex maintains a bullish stance supported by its moving averages, Brooks Laboratories’ share price trajectory highlights a divergence from general market trends. This divergence is underscored by the stock’s consistent underperformance against the BSE500 index over the past three years.
Investors and market observers will note the contrast between the company’s recent positive quarterly results and its longer-term valuation and performance metrics, which continue to weigh on the stock’s market standing.
Market Environment and Sector Dynamics
The Pharmaceuticals & Biotechnology sector has experienced varied performance across its constituents, with some companies benefiting from robust sales growth and innovation pipelines. Brooks Laboratories’ recent sales growth of 4.06% and positive quarterly results align with sector trends, yet the stock’s price action suggests that market participants are factoring in broader concerns related to valuation and profitability metrics.
Overall, Brooks Laboratories’ stock reaching a 52-week low of Rs.93.9 reflects a combination of subdued long-term financial indicators, valuation considerations, and technical factors within a market environment that remains generally positive for the broader indices.
Limited Time Only! Upgrade now and get 1 Year of Stock of the week worth Rs. 14,999 for FREE. Don't miss out on this exclusive offer. Claim Your Free Year →
